CN103272169B - Application of rhodiola rosea compound composite in treating erosive gastritis - Google Patents
Application of rhodiola rosea compound composite in treating erosive gastritis Download PDFInfo
- Publication number
- CN103272169B CN103272169B CN201310259957.3A CN201310259957A CN103272169B CN 103272169 B CN103272169 B CN 103272169B CN 201310259957 A CN201310259957 A CN 201310259957A CN 103272169 B CN103272169 B CN 103272169B
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- medicine
- drug
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of a rhodiola rosea compound composite in preparing a drug for treating erosive gastritis. The drug is prepared by the following active ingredients by in parts by weight: 4.2-7.2 parts of rhodiola rosea, 14-26 parts of poria cocos, 10.5-19.5 parts of dandelion, 10.5-19.5 parts of oriental wormwood, 10.5-19.5 parts of bighead atractylodes rhizome, 7-13 parts of patchouli, 7-13 parts of raw malts, and 3.5-6.5 parts of cardamon. The drug is precise and appropriate in compatibility and less in drug flavor, ensures the drug efficacy, reduces side effects, and can effectively treat the erosive gastritis, and a new selection is provided for clinical administration.
Description
Technical field
The present invention relates to the purposes of a kind of compound Rohoodiola compositions in treatment erosive gastritis.
Background technology
Stomach duodenum ulcer refers to the circular or oval full-thickness defects of the limitation of Grastiodudenal mucosa, and muscularis mucosae is penetrated, and inevitably leaves fibrous scar after healing, and surface is covered by one deck epithelium, and muscularis mucosae can not be regenerated.It is because many reasons causes that gastric acid, pepsin self-digestion or the gastric mucosal barrier to gastric mucosa is destroyed that its cause of disease sums up.Think that in recent years formation and the gastric Helicobacter pylori infection of ulcer also have important relationship.
Chronic erosive gastritis, claims again the indigestion symptoms such as general rarely seen glutted, the pantothenic acid after meal of gastritis verrucosa or varioliform gastritis, belch, irregularities stomachache.There are multiple excipuliforms in Stomach in Patients mucosa, expands folded shape or pimple sample protuberance, diameter 5～10mm, and the visible mucomembranous defect in top or umbilicus sample depression, there is erosion at center, and protuberance is many without blush around, but normal with the similar erythema of size, with gastric antrum, portion is common.
The medicine of the above-mentioned disease of current treatment mostly is chemical drugs, and it is expensive, and side effect is large, and healing required time is long.Therefore, urgent need one is economical and practical, toxic and side effects is low, and the medicine of the above-mentioned disease of energy rapid healing.
And Chinese medicine aspect treatment of chronic diseases one to all playing an important role.Report, with Concha Arcae 75% and Radix Glycyrrhizae 25%, red in pulv, treatment gastric and duodenal ulcers, cure rate reaches 76% (" Chinese medicine voluminous dictionary " second edition, Shanghai science tech publishing house, in March, 2006,548th～549 pages); Also there is people to use Os Sepiae (life) 250g, Concha Arcae (calcined) 250g, Radix Et Rhizoma Rhei 200g, Radix Glycyrrhizae Preparata 200g, grinds to the powder, and boiled water is taken after mixing it with water after meal, each 15g, every day 3～4 times, be used for the treatment of peptic ulcer (Gu Linjiang, Cuttlefish Bone Powder for Peptic Ulcer, journal of shanghai Chinese medicine, 9 phases of calendar year 2001.Also there is people to treat peptic ulcer with Rhizoma Atractylodis Macrocephalae 20g, Poria 20g, Semen Phaseoli 20g, Radix Astragali 15g, Herba Artemisiae Scopariae 15g, Herba Taraxaci 15g, Semen Armeniacae Amarum 10g, Radix Platycodonis 10g, Herba Pogostemonis 10g, Rhizoma Zingiberis 5g, Radix Ginseng 5g, there is good therapeutic effect.
Summary of the invention
The object of the present invention is to provide the purposes of a kind of medicine in treatment erosive gastritis.
The invention provides the purposes of following medicine in the medicine of preparation treatment erosive gastritis; This medicine be the preparation being prepared from by the crude drug of following weight proportion:
Radix Rhodiolae 4.2-7.2 part, Poria 14-26 part, Herba Taraxaci 10.5-19.5 part, Herba Artemisiae Scopariae 10.5-19.5 part, Rhizoma Atractylodis Macrocephalae 10.5-19.5 part, Herba Pogostemonis 7-13 part, Fructus Hordei Germinatus 7-13 part, Fructus Amomi Rotundus 3.5-6.5 part.
Further, this medicine is the preparation being prepared from by the crude drug of following weight proportion:
Radix Rhodiolae 5-7 part, Poria 18-22 part, Herba Taraxaci 13-17 part, Herba Artemisiae Scopariae 13-17 part, Rhizoma Atractylodis Macrocephalae 13-17 part, Herba Pogostemonis 8-12 part, Fructus Hordei Germinatus 8-12 part, Fructus Amomi Rotundus 4-6 part.
Further preferably, this medicine is the preparation being prepared from by the crude drug of following weight proportion:
6 parts of Radix Rhodiolaes, 20 parts, Poria, 15 parts of Herba Taraxacis, 15 parts of Herba Artemisiae Scopariaes, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Herba Pogostemonis, 10 parts of Fructus Hordei Germinatus, 5 parts, Fructus Amomi Rotundus.
Wherein, described Fructus Amomi Rotundus is Fructus Amomi Rotundus.
Wherein, described preparation is pill, capsule, powder, granule, soft capsule, drop pill or oral liquid.
In the present invention, Radix Rhodiolae, is dry root and the rhizome of crassulaceae plants Radix Rhodiolae Rhodiola crenulata (Hool.f.et Thoms.) H.Ohba.Sweet, bitter, flat, return lung, heart channel, benefiting QI for activating blood circulation, promotes blood circulation and relievings asthma.For blood stasis due to qi deficiency, obstruction of qi in the chest and cardialgia, apoplectic hemiplegia, asthenia asthma.
Herba Artemisiae Scopariae is that the quadrate part dryly of feverfew Artemisia scoparia Waldst. et Kit. Artemisia scoparia Waldst.Et Kit. or Herba Artemisiae Scopariae Artemisia capillaries Thunb. divides.Bitter, pungent, be slightly cold, return spleen, stomach, liver, gallbladder meridian.Eliminating damp-heat, promoting the function of the gallbladder to alleviate jaundice.For jaundice oliguria, hygropyrexia heat-damp in summer, eczema pruritus.
The Rhizoma Atractylodis Macrocephalae is the dry rhizome of feverfew Rhizoma Atractylodis Macrocephalae Atractylodes macrocephala Koidz..Bitter, sweet, temperature, returns spleen, stomach warp.Invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, antiabortive.For insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.
Poria is the dry sclerotia of On Polyporaceae Poria Poria cocos (Schw.) Wolf.Sweet, light, flat.GUIXIN, lung, spleen, kidney channel.Promoting diuresis to eliminate damp pathogen, spleen invigorating, mind calming.For edema oliguria, phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, have loose bowels in loose stool, irritability, palpitation with fear insomnia.
Herba Taraxaci is Herba Taraxaci Taraxacum mongolicum Hand.Mazz, alkali ground Herba Taraxaci Taraxacum borealisinense Kitam. or the dry herb that belongs to several plants together.Bitter, sweet, cold.Return liver, stomach warp.Heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, inducing diuresis for treating stranguria syndrome.For furuncle swelling toxin, acute mastitis, scrofula, conjunctival congestion, pharyngalgia, lung abscess, acute appendicitis, jaundice due to damp-heat, the puckery pain of pyretic stranguria.
Herba Pogostemonis is that the quadrate part dryly of labiate Herba Pogostemonis Pogostemon cabl in (Blanco) Benth. divides.Pungent, tepor.Return spleen, stomach, lung meridian.Eliminating turbid pathogen with aromatics, and middle preventing or arresting vomiting, deliver expelling summer-heat.For turbid damp obstructing in middle-JIAO, the vomiting of gastral cavity painful abdominal mass, heat-damp in summer exterior syndrome, hygropyrexia is from the beginning of, heating asthenia, uncomfortable in chestly do not relax, and cold-damp is closed summer-heat, and stomachache is vomited and diarrhoea, nasosinusitis headache.
Compatibility of drugs of the present invention is precise and appropriate, and flavour of a drug are less, has not only ensured drug effect to have reduced side effect, can effectively treat erosive gastritis, for clinical application provides new selection.
Detailed description of the invention
The preparation of embodiment 1 medicine of the present invention
Get Poria 20g, Herba Taraxaci 15g, Herba Artemisiae Scopariae 15g, Rhizoma Atractylodis Macrocephalae 15g, Herba Pogostemonis 10g, Fructus Hordei Germinatus 10g, Radix Rhodiolae 6g, Fructus Amomi Rotundus 5g; First add 4 times of water gagings to soak 10 minutes, then decoct with water 2 times, each 20 minutes, add water 10 times at every turn and measure, filter, merge after decocting liquid, obtain medicine decoction of the present invention.
The preparation of embodiment 2 medicines of the present invention
Poria 20g, Herba Taraxaci 15g, Herba Artemisiae Scopariae 15g, Rhizoma Atractylodis Macrocephalae 15g, Herba Pogostemonis 10g, Fructus Hordei Germinatus 10g, Radix Rhodiolae 6g, Fructus Amomi Rotundus 5g; Decoct with water 3 times, add for the first time 10 times of water gagings and decoct 5 minutes, add for the second time 8 times of water gagings and decoct 10 minutes, add for the third time 8 times of water gagings and decoct 15 minutes, filter, merge after decocting liquid, concentrated, then add proper starch, and granulate, obtain medicinal granule of the present invention.
The preparation of embodiment 3 medicines of the present invention
Get Poria 20g, Herba Taraxaci 15g, Herba Artemisiae Scopariae 15g, Rhizoma Atractylodis Macrocephalae 15g, Herba Pogostemonis 10g, Fructus Hordei Germinatus 10g, Radix Rhodiolae 6g, Fructus Amomi Rotundus 5g; First add 10 times of amount 70% alcoholic solution reflux, extract, 1 time, extract 1 hour, filter, filtrate is for subsequent use, and filtering residue again water decocts 2 times, and 8 times of amounts add water at every turn, each decoction 20 minutes, merge after ethanol extract and decocting liquid, concentrated, then add appropriate microcrystalline Cellulose and dextrin and Radix Rhodiolae powder, after granulation, add appropriate magnesium stearate, tabletting, obtains medicinal tablet of the present invention again.
The preparation of embodiment 4 medicines of the present invention
Get Poria 18g, Herba Taraxaci 17g, Herba Artemisiae Scopariae 17g, Rhizoma Atractylodis Macrocephalae 17g, Herba Pogostemonis 12g, Fructus Hordei Germinatus 12g, Radix Rhodiolae 7g, Fructus Amomi Rotundus 6g; First add 4 times of water gagings to soak 10 minutes, then decoct with water 2 times, each 20 minutes, add water 10 times at every turn and measure, filter, merge after decocting liquid, obtain medicine decoction of the present invention.
The preparation of embodiment 5 medicines of the present invention
Get Poria 22g, Herba Taraxaci 13g, Herba Artemisiae Scopariae 13g, Rhizoma Atractylodis Macrocephalae 13g, Herba Pogostemonis 8g, Fructus Hordei Germinatus 8g, Radix Rhodiolae 5g, Fructus Amomi Rotundus 4g; After pulverizing, cross 80 mesh sieves, then add microcrystalline Cellulose, after mixing, encapsulated, obtain medicine capsule of the present invention.
Further show beneficial effect of the present invention by concrete test example below.
The treatment of test example 1 medicine of the present invention to gastric ulcer
Gastric Ulcer standard: upper abdomen dull pain, dull pain or burn sample pain, after taking alkalescent medicine, alleviate, such pain has rhythmicity, how in 1 hour after the meal, to occur, after 1～2 hour, alleviate gradually, generally also there will be acid regurgitation, heating installation, heartburn, Abdeminal pain, feel sick, the indigestion symptom such as vomiting; The visible niche of upper digestive tract radiography; Endoscopy, can in stomach see circle or oval, bottom is smooth, the ulcer of neat in edge, ulcer surface is greyish white or brown tongue film covers, edge swelling, color and luster ruddy, smooth and soft (being gastric ulcer active stage).Accept altogether 30 examples for medical treatment, endoscopy is confirmed as gastric ulcer.
Criterion of cure: epigastrium pain disappears, endoscopy, visible ulcer surface white fur disappears, becomes red congested cicatrix, and visible pleat is concentrated (being cicatricial phase).
Effectively standard: epigastrium pain disappears or alleviates, endoscopy, the attenuation of tongue film, ulcer is dwindled, and it is the blush of visible mucous epithelium regeneration around; Or ulcer surface almost disappears, on it, there is few thin coating (being healing stage).
Therapeutic Method: get the decoction that embodiment 1 prepares, every bu is taken for 3 times, period in a medicine, avoids eating anything raw or cold, maror.
Criterion of cure: take medicine continuously by Therapeutic Method, treat 20～30 days, cure 30 examples, account for 100% of total case.
The treatment of test example 2 medicine of the present invention to duodenal ulcer
Duodenal ulcer diagnostic criteria: epigastrium dull pain, causalgia, distending pain or severe pain, also can be only dull pain discomfort in the time of hunger, or there is rest pain under slight or moderate xiphoid-process, can be alleviated by antacid or feed, early within 1～3 hour after the meal, start to occur upper abdominal pain, will continue to lunch if do not taken medicine or taking food after, just alleviate, food also must have meal to alleviate for latter 2～4 hours again bitterly.Endoscopy, thick fur and filth can have petechia, sludged blood on it, the obvious congestion and edema erosion of mucosa around; Or tongue is still thicker, around mucosal inflammation edema alleviates, and red re-epithelialize (active stage) can appear in ulcer edge.Accept altogether 27 examples for medical treatment, endoscopy is confirmed as duodenal ulcer.
Therapeutic Method: with test example 1.
Criterion of cure: pain disappears, endoscopy, white fur disappears, and replaces red epithelium and cicatrix; Or re-epithelialize redness disappears, cicatrix color white (being cicatricial phase).Take medicine continuously by Therapeutic Method, treat 15～20 days, cure 27 examples, account for 100% of total case.
The treatment of test example 3 medicine of the present invention to chronic erosive gastritis
Chronic erosive gastritis diagnostic criteria: occur the indigestion symptoms such as glutted, acid regurgitation, heating installation, irregularities stomachache, can occur massive bleeding from upper digestive tract, occur hematemesis, melena, shock, normal easily recurrence after stopped bleeding; Endoscopy, visible gastric mucosa congestion and edema, the erosion of some lamellar, the multiple ulcer differing in size, ulcer surface can have fresh go out clot.Accept altogether 50 examples for medical treatment, endoscopy is confirmed as chronic erosive gastritis.
Therapeutic Method: with test example 1.
Criterion of cure: the indigestion symptoms such as acid regurgitation, stomachache disappear, endoscopy, without point-like or lamellar erosion, mucosa edema disappears, and gastric mucosa heals.Take medicine continuously by Therapeutic Method, treat 15～30 days, cure 50 examples, account for 100% of total case.
Model case 1
Jiang, man, 32 years old, stomach felt there is feeling of repletion, obvious especially when rise morning, after meal or close on ante cibum and have belch phenomenon, and anorexia, body weight obviously alleviates; Through gastroscopy, confirm as erosive gastritis.
Take medicine after 7 days by test example 1 method, feeling of repletion, belch phenomenon are alleviated, and after 15 days, it is suitable with normal period that appetite has recovered, swollen sense, belch phenomenon disappear, after 25 days, through gastroscopy, ulcer surface heals, and conscious appetite, stomach feel good, and body weight is gone up.
The therapeutical effect of test example 4 pharmaceutical composition of the present invention to acetic acid type gastric ulcer
Get SD rat, fasting is after 12 hours, and rats by intraperitoneal injection 3% is anaesthetized without barbital sodium, with the alcohol cotton stick skin of sterilizing, cut abdominal cavity open, in glandular stomach portion, antetheca hole body intersection serosal surface sticks the circular filter paper 30s that soaks into glacial acetic acid, diameter 5mm, repeat 3 times, close abdomen sewing-up cut, be coated with penicillin.Postoperative routine feeding, is divided into 6 groups at random by animal on the 4th day, and 10 every group, male and female half and half, are respectively model group (10mlkg
-1distilled water), pharmaceutical composition of the present invention senior middle school low dose group (be followed successively by 20,40,80g crude drug/kg body weight), contrast groups A (20g crude drug/kg body weight), contrast groups B (20g crude drug/kg body weight), positive drug ranitidine group (30mgkg
-1).The 2nd day after grouping starts gastric infusion, administration every day 1 time, and dosage is 10mlkg
-1, continuous 5 days, last administration is de-cervical vertebra execution animal after 12 hours, cut open the belly and get stomach, wash gastric content with normal saline, stomach is fixed in 10% formaldehyde, after 15 minutes, stomach is lain on glass surface ware, under magnifier, measure major diameter and the minor axis of ulcer surface with slide gauge, and calculate ulcer surface.
Calculate ulcer inhibition rate: ulcer inhibition rate=(matched group ulcer area-administration group ulcer area)/matched group ulcer area x100%, observes ulcer healing degree.
Pharmaceutical composition of the present invention is prepared by embodiment 1;
The preparation method of contrast groups A medicine is as follows:
Get Fructus Amomi Rotundus 10g, Rhizoma Atractylodis Macrocephalae 20g, Poria 20g, Herba Pogostemonis 15g, Herba Taraxaci 15g, Radix Ginseng 5g, Folium Perillae 10g, Semen Armeniacae Amarum 10g, Semen Coicis 20g, Herba Artemisiae Scopariae 15g; First add 4 times of water gagings to soak 10 minutes, then decoct with water 2 times, each 20 minutes, add water 10 times at every turn and measure, filter, merge after decocting liquid, obtain contrast groups A decoction.
The preparation method of contrast groups B medicine is as follows:
20 parts of Semen Coiciss, 20 parts of Semen Benincasaes, 15 parts of Herba Artemisiae Scopariaes, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Folium Perillaes, 10 parts of Semen Armeniacae Amarums, 10 parts of Semen Lablab Albums, 10 parts of Semen Myristicaes, 10 parts of the Radixs Astragali, 5 parts of Radix Ginsengs, 5 parts of Fructus Forsythiaes.First add 4 times of water gagings to soak 10 minutes, then decoct with water 2 times, each 20 minutes, add water 10 times at every turn and measure, filter, merge after decocting liquid, obtain contrast groups B decoction.
Experimental result is in table 1.
Table 1
Note: compared with model group, * is p < 0.05, and * * is p < 0.01; Compared with contrast groups A, Δ is p < 0.05; Compared with contrast groups B, a is p < 0.05.
As shown in Table 1, pharmaceutical composition of the present invention, can effectively treat gastric ulcer, meanwhile, compared with contrast groups A, although ingredients is similar, but the drug activity of pharmaceutical composition of the present invention under Isodose is obviously better than contrast groups A (p < 0.05).Compared with contrast groups B, the drug activity under Isodose is suitable, but present composition flavour of a drug still less.Above-mentioned test shows, pharmaceutical composition compatibility of the present invention is precise and appropriate, has brought into play synergistic function.
The therapeutical effect of test example 5 pharmaceutical composition of the present invention to duodenal ulcer rat model
Get SD rat, male and female half and half, after anesthesia, by improvement Okabe method, get the glass tubing of internal diameter 3mm, vertical flicking on 0.5cm place duodenum antetheca serosal surface, injects 70% acetic acid 0.075ml, after 15s under pylorus in this pipe, sucking-off acetic acid, closes abdomen, obtains duodenal ulcer model.Postoperative 4 days, rat is divided into model group (10mlkg
-1distilled water), pharmaceutical composition of the present invention senior middle school low dose group (be followed successively by 20,40,80g crude drug/kg body weight), contrast groups A (20g crude drug/kg body weight), contrast groups B (20g crude drug/kg body weight), positive drug omeprazole group (pressing quantity converts), gavage, after 7 days, is put to death rat respectively, takes out duodenum and observes ulcer inhibition rate.
Pharmaceutical composition of the present invention is prepared by embodiment 1;
The preparation method of contrast groups A medicine is as follows:
Get Fructus Amomi Rotundus 10g, Rhizoma Atractylodis Macrocephalae 20g, Poria 20g, Herba Pogostemonis 15g, Herba Taraxaci 15g, Radix Ginseng 5g, Folium Perillae 10g, Semen Armeniacae Amarum 10g, Semen Coicis 20g, Herba Artemisiae Scopariae 15g; First add 4 times of water gagings to soak 10 minutes, then decoct with water 2 times, each 20 minutes, add water 10 times at every turn and measure, filter, merge after decocting liquid, obtain contrast groups A decoction.
The preparation method of contrast groups B medicine is as follows:
20 parts of Semen Coiciss, 20 parts of Semen Benincasaes, 15 parts of Herba Artemisiae Scopariaes, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Folium Perillaes, 10 parts of Semen Armeniacae Amarums, 10 parts of Semen Lablab Albums, 10 parts of Semen Myristicaes, 10 parts of the Radixs Astragali, 5 parts of Radix Ginsengs, 5 parts of Fructus Forsythiaes.First add 4 times of water gagings to soak 10 minutes, then decoct with water 2 times, each 20 minutes, add water 10 times at every turn and measure, filter, merge after decocting liquid, obtain contrast groups B decoction.
The results are shown in Table 2.
Table 2
Note: compared with model group, * is p < 0.05, expects for p < 0.01; Compared with contrast groups A, Δ is p < 0.05; Compared with contrast groups B, a is p < 0.05.
As shown in Table 2, pharmaceutical composition of the present invention, can effectively treat duodenal ulcer, simultaneously, compared with contrast groups A, although ingredients is similar,, the drug activity of pharmaceutical composition of the present invention under Isodose is obviously better than contrast groups A (p < 0.05); Compared with contrast groups B, the drug activity under Isodose is suitable, but present composition flavour of a drug still less.Above-mentioned test shows, pharmaceutical composition compatibility of the present invention is precise and appropriate, has brought into play synergistic function.
Test example 6 contrasts with the clinical drug effect of contrast groups B
Except above-mentioned case, case totally 17 people that also accepted erosive gastritis for medical treatment, all use following prescription to treat: 20 parts of Semen Coiciss, 20 parts of Semen Benincasaes, 15 parts of Herba Artemisiae Scopariaes, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Folium Perillaes, 10 parts of Semen Armeniacae Amarums, 10 parts of Semen Lablab Albums, 10 parts of Semen Myristicaes, 10 parts of the Radixs Astragali, 5 parts of Radix Ginsengs, 5 parts of Fructus Forsythiaes.
Treat after 10 days, more than 90% patient thinks that epigastric discomfort slows down or disappears, and appetite improves, and shows that its peptic ulcer has taken a favorable turn or healing trend, but most of patients is after medication, flatulence in the lower abdomen, and empty respectful number of times obviously increases.
And adopt medicine of the present invention to treat, there is not the side effect such as flatulence in the lower abdomen in patient, and cure rate is high, shows that the present invention is changing after the flavour of a drug composition and medical material consumption of prescription, not only ensured curative effect, also reduced side effect.
In sum, compatibility of drugs of the present invention is precise and appropriate, and flavour of a drug are less, has not only ensured drug effect to have reduced side effect, can effectively treat erosive gastritis, for clinical application provides new selection.
Claims (4)
1. the purposes of following compound Rohoodiola compositions in the medicine of preparation treatment erosive gastritis; This medicine is the preparation being prepared from by the crude drug of following weight proportion:
Radix Rhodiolae 4.2-7.2 part, Poria 14-26 part, Herba Taraxaci 10.5-19.5 part, Herba Artemisiae Scopariae 10.5-19.5 part, Rhizoma Atractylodis Macrocephalae 10.5-19.5 part, Herba Pogostemonis 7-13 part, Fructus Hordei Germinatus 7-13 part, Fructus Amomi Rotundus 3.5-6.5 part.
2. purposes according to claim 1, is characterized in that: this medicine is the preparation being prepared from by the crude drug of following weight proportion:
Radix Rhodiolae 5-7 part, Poria 18-22 part, Herba Taraxaci 13-17 part, Herba Artemisiae Scopariae 13-17 part, Rhizoma Atractylodis Macrocephalae 13-17 part, Herba Pogostemonis 8-12 part, Fructus Hordei Germinatus 8-12 part, Fructus Amomi Rotundus 4-6 part.
3. purposes according to claim 2, is characterized in that: this medicine is the preparation being prepared from by the crude drug of following weight proportion:
6 parts of Radix Rhodiolaes, 20 parts, Poria, 15 parts of Herba Taraxacis, 15 parts of Herba Artemisiae Scopariaes, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Herba Pogostemonis, 10 parts of Fructus Hordei Germinatus, 5 parts of Fructus Amomi Rotunduss.
4. according to the purposes described in claim 1-3 any one, it is characterized in that: described preparation is pill, capsule, powder, granule, drop pill or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310259957.3A CN103272169B (en) | 2013-06-26 | 2013-06-26 | Application of rhodiola rosea compound composite in treating erosive gastritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310259957.3A CN103272169B (en) | 2013-06-26 | 2013-06-26 | Application of rhodiola rosea compound composite in treating erosive gastritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103272169A CN103272169A (en) | 2013-09-04 |
| CN103272169B true CN103272169B (en) | 2014-08-27 |
Family
ID=49054508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310259957.3A Active CN103272169B (en) | 2013-06-26 | 2013-06-26 | Application of rhodiola rosea compound composite in treating erosive gastritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103272169B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105214037A (en) * | 2015-09-30 | 2016-01-06 | 成都恒凌科技有限公司 | The solid dispersal capsule for the treatment of peptic ulcer |
| CN105250943A (en) * | 2015-09-30 | 2016-01-20 | 成都恒凌科技有限公司 | Aqueous extract capsules for treating peptic ulcers |
| CN105250944A (en) * | 2015-09-30 | 2016-01-20 | 成都恒凌科技有限公司 | Capsules for treating peptic ulcers |
| CN105250951A (en) * | 2015-09-30 | 2016-01-20 | 成都恒凌科技有限公司 | Preparing method for medicine for treating peptic ulcer |
| CN105214030A (en) * | 2015-09-30 | 2016-01-06 | 成都恒凌科技有限公司 | The purposes of a kind of pharmaceutical composition in the medicine of preparation treatment gastric ulcer |
| CN105194609A (en) * | 2015-09-30 | 2015-12-30 | 成都恒凌科技有限公司 | Pharmaceutical composition for treating peptic ulcers |
| CN105233201A (en) * | 2015-09-30 | 2016-01-13 | 成都恒凌科技有限公司 | Solid dispersible granules for treating peptic ulcers |
| CN105214034A (en) * | 2015-09-30 | 2016-01-06 | 成都恒凌科技有限公司 | The powder for the treatment of peptic ulcer |
| CN105233202A (en) * | 2015-09-30 | 2016-01-13 | 成都恒凌科技有限公司 | Preparation method of drug for treating peptic ulcers and extractive prepared according to preparation method |
| CN105194608A (en) * | 2015-09-30 | 2015-12-30 | 成都恒凌科技有限公司 | Micro-powder capsule for treating peptic ulcers |
| CN105214033A (en) * | 2015-09-30 | 2016-01-06 | 成都恒凌科技有限公司 | The purposes of a kind of pharmaceutical composition in the medicine of preparation treatment duodenal ulcer |
| CN105214038A (en) * | 2015-09-30 | 2016-01-06 | 成都恒凌科技有限公司 | The micropowder tablet for the treatment of peptic ulcer |
| CN105250946A (en) * | 2015-09-30 | 2016-01-20 | 成都恒凌科技有限公司 | Solid dispersion for treating peptic ulcers |
| CN105214035A (en) * | 2015-09-30 | 2016-01-06 | 成都恒凌科技有限公司 | One treats peptic ulcer tablet and preparation method thereof |
| CN105214031A (en) * | 2015-09-30 | 2016-01-06 | 成都恒凌科技有限公司 | A kind of water extract granule for the treatment of peptic ulcer |
| CN105233199A (en) * | 2015-09-30 | 2016-01-13 | 成都恒凌科技有限公司 | Micro-powder granules for treating digestive ulcer |
| CN105250942A (en) * | 2015-09-30 | 2016-01-20 | 成都恒凌科技有限公司 | Application of medicine composition in preparation of medicine for treating erosive gastritis |
| CN105214032A (en) * | 2015-09-30 | 2016-01-06 | 成都恒凌科技有限公司 | The solid dispersion tablet for the treatment of peptic ulcer |
| CN105250945A (en) * | 2015-09-30 | 2016-01-20 | 成都恒凌科技有限公司 | Aqueous extract tablets for treating peptic ulcers |
| CN105233200A (en) * | 2015-09-30 | 2016-01-13 | 成都恒凌科技有限公司 | Tablets for treating digestive ulcer |
| CN105288530A (en) * | 2015-09-30 | 2016-02-03 | 成都恒凌科技有限公司 | Capsule for treating peptic ulcer and preparation method of capsule |
| CN105194611A (en) * | 2015-09-30 | 2015-12-30 | 成都恒凌科技有限公司 | Granule for treating peptic ulcer and preparation method of granule |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288765A (en) * | 2008-05-15 | 2008-10-22 | 天科仁祥技术（北京）有限责任公司 | Medicine composition for promoting digestion and removing indigestion and its preparation method |
| CN102552795A (en) * | 2012-03-09 | 2012-07-11 | 通化斯威药业股份有限公司 | Drug capable of increasing gastric motility and treating chronic gastritis and preparation method thereof |
-
2013
- 2013-06-26 CN CN201310259957.3A patent/CN103272169B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288765A (en) * | 2008-05-15 | 2008-10-22 | 天科仁祥技术（北京）有限责任公司 | Medicine composition for promoting digestion and removing indigestion and its preparation method |
| CN102552795A (en) * | 2012-03-09 | 2012-07-11 | 通化斯威药业股份有限公司 | Drug capable of increasing gastric motility and treating chronic gastritis and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 疣状胃炎的研究现状及中医治疗进展;贾晓东;《实用中西医结合临床》;20091130;第9卷(第6期);第90-92页 * |
| 贾晓东.疣状胃炎的研究现状及中医治疗进展.《实用中西医结合临床》.2009,第9卷(第6期),第90-92页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103272169A (en) | 2013-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103272169B (en) | Application of rhodiola rosea compound composite in treating erosive gastritis | |
| CN103285309B (en) | Rhodiola rosea compound composition for treating peptic ulcer | |
| CN103285310B (en) | Use of rhodiola rosea compound composition in preparing medicine for curing gastric ulcer | |
| CN105233202A (en) | Preparation method of drug for treating peptic ulcers and extractive prepared according to preparation method | |
| CN103272170B (en) | Application of rhodiola rosea compound composite in preparing drug for treating duodenal ulcer | |
| CN104138550A (en) | Preparation method of medicine for treating peptic ulcers | |
| CN105214032A (en) | The solid dispersion tablet for the treatment of peptic ulcer | |
| CN102416121B (en) | Application of medicinal composition in preparation of medicaments for treating gastric ulcer | |
| CN102416120B (en) | Application of medicinal composition in preparation of medicament for treating erosive gastritis | |
| CN102430073B (en) | Medicinal composition for treating peptic ulcer | |
| CN105214031A (en) | A kind of water extract granule for the treatment of peptic ulcer | |
| CN105214035A (en) | One treats peptic ulcer tablet and preparation method thereof | |
| CN105250946A (en) | Solid dispersion for treating peptic ulcers | |
| CN105233201A (en) | Solid dispersible granules for treating peptic ulcers | |
| CN105214037A (en) | The solid dispersal capsule for the treatment of peptic ulcer | |
| CN104138553A (en) | Pharmaceutical composition for treating peptic ulcer | |
| CN104138551A (en) | Application of pharmaceutical composition in preparation of medicaments for treating duodenal ulcer | |
| CN102416122B (en) | Application of medicinal composition in preparation of medicaments for treating duodenal ulcer | |
| CN105250951A (en) | Preparing method for medicine for treating peptic ulcer | |
| CN105194608A (en) | Micro-powder capsule for treating peptic ulcers | |
| CN105214030A (en) | The purposes of a kind of pharmaceutical composition in the medicine of preparation treatment gastric ulcer | |
| CN116617290A (en) | Traditional Chinese medicine composition for treating diabetic foot disease | |
| CN105194609A (en) | Pharmaceutical composition for treating peptic ulcers | |
| CN105250942A (en) | Application of medicine composition in preparation of medicine for treating erosive gastritis | |
| CN105250945A (en) | Aqueous extract tablets for treating peptic ulcers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |